Biotech ETF
When you think of biotechnology, you might imagine lab coats, gene editing, and breakthrough drugs. But for investors, biotech represents a high growth, high volatility sector that can be difficult to navigate one stock at a time. That is where the biotech ETF comes in. An exchange traded fund focused on biotechnology offers diversified exposure to dozens of companies, from early stage innovators to established pharmaceutical giants. With recent shifts in interest rates, FDA approval trends, and merger activity, the biotech ETF landscape has become especially compelling in 2025.
What Is a Biotech ETF and Why Does It Matter?
A biotech ETF is a basket of stocks that tracks a specific index of biotechnology companies. Instead of buying shares in a single firm like Moderna or Amgen, you invest in the entire sector. This approach reduces the risk of any one company’s clinical trial failure or regulatory setback wiping out your portfolio.
Why does this matter? Biotech is notoriously binary. A single Phase 3 trial result can send a stock up 200% or down 80% in a day. An ETF smooths out those extremes. Moreover, ETFs offer liquidity, low expense ratios (often below 0.50%), and easy accessibility through standard brokerage accounts. For investors who believe in the long term potential of genomics, precision medicine, and biologics but do not want to bet on a single horse, a biotech ETF is the vehicle of choice.
Recent News and Performance Trends
The biotech ETF sector has experienced a notable resurgence in the first half of 2025. After a challenging 2023 and 2024 marked by rising interest rates and cautious venture capital funding, several catalysts have emerged.
First, the Federal Reserve has signaled a potential pause or gradual reduction in rates. Lower borrowing costs are a tailwind for biotech because these companies often burn cash for years before generating revenue. Cheaper capital makes it easier for them to fund research and development. Second, the FDA has accelerated its review of novel therapies. In Q1 2025 alone, the agency approved 15 new drugs, including two gene therapies and a first in class treatment for Alzheimer’s disease.
Major biotech ETFs, such as the iShares Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI), have gained 12% to 18% year to date. The XBI, which is equal weight and thus more exposed to small cap biotechs, has outperformed the market cap weighted IBB, reflecting a “risk on” appetite among investors.
Key Factors Driving Biotech ETFs in 2025
Several underlying dynamics are influencing biotech ETF performance right now. Understanding them can help you decide whether to allocate capital to this subsector.
Interest Rates and Financing Environment
As noted, lower rates reduce the cost of debt and equity financing. Many pre revenue biotechs depend on secondary offerings or partnerships. A stable rate environment allows them to plan longer runways.
Merger and Acquisition Activity
Large pharmaceutical companies are sitting on record cash reserves. They need to replenish their pipelines, and small biotechs with promising assets are attractive targets. M&A activity drives up share prices of acquired companies and often lifts the entire sector. In 2025, we have already seen several deals above $2 billion, including an acquisition in the oncology space that boosted the holdings of many funds.
Regulatory Tailwinds
The FDA’s new “modernization” initiative aims to reduce the time to market for breakthrough therapies. This includes using real world evidence and alternative trial designs. Faster approvals mean revenue comes sooner, which directly improves a biotech company’s valuation.
Inflation and Healthcare Spending
Healthcare spending continues to grow globally. Biologics and gene therapies command high prices, and demand is inelastic. This provides a fundamental revenue floor for the largest holdings in most biotech ETFs.
How to Choose the Right Biotech ETF
Not all biotech ETFs are created equal. The right choice depends on your risk tolerance, investment horizon, and exposure preferences. Below is a quick comparison of the two most popular funds.
| ETF | Ticker | Expense Ratio | Focus | Top Holdings |
|---|---|---|---|---|
| iShares Biotechnology ETF | IBB | 0.45% | Large cap, market cap weighted | Amgen, Gilead, Vertex |
| SPDR S&P Biotech ETF | XBI | 0.35% | Equal weight across index | Moderna, Exact Sciences, Ionis |
IBB is more conservative, leaning toward mega cap firms with stable cash flows. XBI offers higher upside potential but also greater volatility because of its smaller company tilt.
For a pure play on genomics and gene editing, consider the ARK Genomic Revolution ETF (ARKG), although its actively managed strategy carries a higher fee (0.75%) and concentration risk.
Before investing, review the fund’s holdings, performance relative to the S&P 500, and the expense ratio. Also watch for any recent dividend distributions; biotech ETFs tend to pay very low dividends because most companies reinvest earnings into R&D.
Final Thoughts
Biotech ETFs provide a balanced way to tap into one of the most innovative sectors of the economy. The recent news cycle, including falling rates, robust drug approvals, and heavy M&A, suggests that 2025 could be a strong year for these funds. Whether you choose a market cap weighted or equal weight approach, the key is to remain diversified and patient. Biotech is not a short term trade; it is a long term conviction play on the future of medicine.
Written by Zubair Khalid, DVM, MS, PhD. Source: [original news feed and industry reports].